TNGXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Tango Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$23.53+1.49 (+6.76%)
Close on Oct 19, 2026
- Market cap
- $3.53B
- P/E (TTM)
- –
- Dividend yield
- –
Share price
+$14.50 (+160.6%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Tango Therapeutics, Inc. grew revenue 121.5% to $53.81M over the twelve months to Jun 30, 2026. Free cash flow was -$144.25M.
Revenue
$53.81M
+121.5% vs. a year earlier
Operating income
-$136.35M
TTM Q2 2026
Free cash flow
-$144.25M
TTM Q2 2026
EPS, diluted
-$0.85
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $3.53B
- P/E ratio
- –
- Price to sales
- 65.54
- Price to book
- 3.44
- Dividend yield
- –
- Free cash flow yield
- -4.09%
Fundamentals
- Revenue
- $53.81M
- Net income
- -$123.72M
- EPS, diluted
- -$0.85
- Free cash flow
- -$144.25M
- Book value per share
- $6.84
- Diluted shares
- 150M
Seven years at a glance
Fiscal years 2019 to 2025 and trailing twelve months, USD
Revenue
$53.81M+121.5% YoY
Operating income
-$136.35M
Net income
-$123.72M
EPS, diluted
-$0.85
Free cash flow
-$144.25M
Reported periodTrailing twelve months